Precision Medicine

Dell and TGen Extend Partnership in Precision Medicine Effort

IT provider Dell Inc. has extended its partnership with the Translational Genomics Research Institute (TGen) to assist researchers and physicians expand the reach and impact of precision medicine efforts for pediatric cancer. The companies announced their extended partnership, aimed at helping clinical researchers and physicians expand globally the reach and …

Read More »

BioMarin Files for Approval of its Duchenne Muscular Dystrophy Drug in Europe

BioMarin Pharmaceutical Inc. has filed for European approval of its investigational drug for a rare, genetic disorder that causes progressive muscle wasting. The company said that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for drisapersen, an investigational antisense oligonucleotide drug candidate for the …

Read More »

FDA Grants Priority Review to Merck’s Keytruda for Treatment of Lung Cancer

Merck said that the US Food and Drug Administration (FDA) has accepted an application for an expanded approval of its anti-PD-1 therapy, Keytruda (pembrolizumab), and granted the drug priority review. Merck announced that the agency has accepted for review the supplemental Biologics License Application (sBLA) for Keytruda for the treatment …

Read More »

Bluebird Bio Enters CAR T Deal with Five Prime

Bluebird bio announced that it has entered into an immuno-oncology deal with Five Prime Therapeutics. The companies said that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies. Under the agreement, the companies will use Five Prime’s proprietary human …

Read More »

Biodesix Launches its Liquid Biopsy Mutation Test for Lung Cancer Patients

Biodesix, Inc. has launched its targeted liquid biopsy mutation test for patients with advanced lung cancer. The molecular diagnostics company announced the launch of GeneStrat, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC). The results from the blood test are …

Read More »

Celgene to Use Cypher’s Technology to Discover Genomic Biomarkers

Genome informatics company Cypher Genomics, Inc. will use its diagnostics technology to assist Celgene in discovering novel genomic biomarkers that identify patients who respond well to specific drugs. The collaboration comes during industry’s push in increasing efforts in precision medicine, tailoring therapy based on a patient’s genetic makeup. The companies announced …

Read More »

Evolution of Healthcare Driven by Science, Information and Technology

Advances in science, more readily available medical information and new technologies are driving evolution of global healthcare increasing patient engagement, improving diagnosis and treatment and enabling patients with life-threatening diseases to live longer and healthier lives, according to CSL Limited CEO and Managing Director Paul Perreault. “It’s all about diagnosing …

Read More »

FDA Clears Roche’s KRAS Mutation Test for Colorectal Cancer Patients

Today, Roche announced that US health regulators have approved its diagnostic test for a certain gene mutation in patients with advanced colorectal cancer. The company said that the US Food and Drug Administration (FDA) approved the cobas KRAS Mutation Test for diagnostic use. The real-time polymerase chain reaction (PCR) test …

Read More »

Yale Researchers Successfully Correct Most Common Cystic Fibrosis Mutation

Researchers at Yale University have used gene editing to successfully correct the most common mutation in the gene that causes cystic fibrosis (CF). A multidisciplinary team of Yale researchers developed a novel approach to edit the genetic defect. In order to correct the mutation, the team used synthetic molecules similar …

Read More »

Study Finds Adaptive Biotechnologies’ Next-Generation Sequencing-Based Technology Can Detect Hodgkin Lymphoma Disease Recurrence

Adaptive Biotechnologies’ next-generation genetic diagnostic technology has demonstrated the potential to detect trace amounts of classical Hodgkin’s lymphoma (CHL) that remains in the body after treatment. Researchers at The University of Texas MD Anderson Cancer Center conducted a study showing that Adaptive Biotechnologies’ next-generation sequencing-based approach to identification and quantification …

Read More »